FB825

DRUG5 trials

Sponsors

Fountain Biopharma Inc., Oneness Biotech Co., Ltd.

Conditions

Allergic AsthmaAtopic DermatitisHealthy

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

CompletedNCT02309762

Fountain Biopharma Inc.Healthy

Start: 2015-03-31End: 2016-02-29Updated: 2016-02-04

Phase 2

Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis

Oneness Biotech Co., Ltd.Atopic Dermatitis

Start: 2020-03-10End: 2022-06-30Updated: 2022-04-04

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

RecruitingNCT05008965

Oneness Biotech Co., Ltd.Allergic Asthma

Start: 2021-07-27End: 2027-12-31Target: 100Updated: 2026-01-12

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

CompletedNCT05059509

Oneness Biotech Co., Ltd.Atopic Dermatitis

Start: 2020-02-06End: 2022-03-31Updated: 2022-04-04

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

RecruitingNCT06397911

Oneness Biotech Co., Ltd.Atopic Dermatitis

Start: 2024-08-08End: 2027-05-31Target: 114Updated: 2026-06-15